ANAPTYSBIO, INC. Operating Expenses
ANAPTYSBIO, INC. (ANAB) reported Operating Expenses of $20.72 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-09-21
- ANAPTYSBIO, INC. operating expenses for the quarter ending 2026-06-30 was -$39.47M, a 181.50% decline year-over-year.
- ANAPTYSBIO, INC. operating expenses for the quarter ending 2026-03-31 was $60.19M, a 8.83% increase year-over-year.
- ANAPTYSBIO, INC. operating expenses for the quarter ending 2025-12-31 was -$137.66M.
- ANAPTYSBIO, INC. operating expenses for the quarter ending 2025-09-30 was $41.62M, a 21.14% decline year-over-year.
- ANAPTYSBIO, INC. operating expenses for fiscal 2025 was $7.70M, a 69.35% decline from fiscal 2024.
- ANAPTYSBIO, INC. operating expenses for fiscal 2024 was $25.13M, a 86.16% decline from fiscal 2023.
- ANAPTYSBIO, INC. operating expenses for fiscal 2023 was $181.57M, a 44.74% increase from fiscal 2022.
- ANAPTYSBIO, INC. operating expenses for fiscal 2022 was $125.44M, a 4.54% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$39.47M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $20.72M 10-KT · filed 2026-09-21 | -$116.94M derived: sum of 3 quarters · filed 2026-09-21 | -$75.32M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2026-03-31 | $60.19M 10-Q · filed 2026-05-12 | -$77.47M derived: sum of 2 quarters · filed 2026-09-21 | -$35.85M derived: sum of 3 quarters · filed 2026-09-21 | $12.58M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-12-31 | -$137.66M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | -$96.04M derived: sum of 2 quarters · filed 2026-09-21 | -$47.61M derived: sum of 3 quarters · filed 2026-09-21 | $7.70M 10-KT · filed 2026-09-21 | $186.71M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $41.62M 10-Q · filed 2025-11-04 | $90.05M derived: sum of 2 quarters · filed 2025-11-04 | $145.36M 10-Q · filed 2025-11-04 | $17.04M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-06-30 | $48.43M 10-Q · filed 2025-08-06 | $6.57M 10-KT · filed 2026-09-21 | $103.74M 10-Q · filed 2025-08-06 | -$24.57M derived: sum of 3 quarters · filed 2026-09-21 | $28.20M derived: sum of 4 quarters · filed 2026-09-21 | |
| 2025-03-31 | $55.31M 10-Q · filed 2026-05-12 | -$73.01M derived: sum of 2 quarters · filed 2026-09-21 | -$20.23M derived: sum of 3 quarters · filed 2026-09-21 | $31.06M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2024-12-31 | -$128.32M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | -$75.54M derived: sum of 2 quarters · filed 2026-09-21 | -$24.25M derived: sum of 3 quarters · filed 2026-09-21 | $25.13M 10-KT · filed 2026-09-21 | $206.23M 10-K · filed 2025-02-27 | |
| 2024-09-30 | $52.77M 10-Q · filed 2025-11-04 | $104.07M derived: sum of 2 quarters · filed 2025-11-04 | $153.45M 10-Q · filed 2025-11-04 | $204.59M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-06-30 | $51.29M 10-Q · filed 2025-08-06 | $100.67M 10-Q · filed 2025-08-06 | $151.81M derived: sum of 3 quarters · filed 2026-03-03 | $192.86M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-03-31 | $49.38M 10-Q · filed 2025-05-05 | $100.52M derived: sum of 2 quarters · filed 2026-03-03 | $141.57M derived: sum of 3 quarters · filed 2026-03-03 | $185.17M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2023-12-31 | $51.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $92.19M derived: sum of 2 quarters · filed 2026-03-03 | $135.79M derived: sum of 3 quarters · filed 2026-03-03 | $181.57M 10-K · filed 2026-03-03 | ||
| 2023-09-30 | $41.05M 10-Q · filed 2024-11-05 | $84.65M derived: sum of 2 quarters · filed 2024-11-05 | $130.43M 10-Q · filed 2024-11-05 | $163.21M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $43.60M 10-Q · filed 2024-08-05 | $89.38M 10-Q · filed 2024-08-05 | $122.16M derived: sum of 3 quarters · filed 2025-02-27 | $153.09M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $45.77M 10-Q · filed 2024-05-09 | $78.56M derived: sum of 2 quarters · filed 2025-02-27 | $109.48M derived: sum of 3 quarters · filed 2025-02-27 | $138.50M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $32.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $63.71M derived: sum of 2 quarters · filed 2025-02-27 | $92.72M derived: sum of 3 quarters · filed 2025-02-27 | $125.44M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $30.93M 10-Q · filed 2023-11-02 | $59.94M derived: sum of 2 quarters · filed 2023-11-02 | $92.66M 10-Q · filed 2023-11-02 | $124.83M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-06-30 | $29.02M 10-Q · filed 2023-08-07 | $61.73M 10-Q · filed 2023-08-07 | $93.90M derived: sum of 3 quarters · filed 2024-03-11 | $121.56M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-03-31 | $32.72M 10-Q · filed 2023-05-11 | $64.89M derived: sum of 2 quarters · filed 2024-03-11 | $92.54M derived: sum of 3 quarters · filed 2024-03-11 | $123.10M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2021-12-31 | $32.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $59.82M derived: sum of 2 quarters · filed 2024-03-11 | $90.38M derived: sum of 3 quarters · filed 2024-03-11 | $119.99M 10-K · filed 2024-03-11 | ||
| 2021-09-30 | $27.65M 10-Q · filed 2022-11-08 | $58.21M derived: sum of 2 quarters · filed 2022-11-08 | $87.82M 10-Q · filed 2022-11-08 | $114.48M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $30.56M 10-Q · filed 2022-08-08 | $60.17M 10-Q · filed 2022-08-08 | $86.82M derived: sum of 3 quarters · filed 2023-03-01 | $111.16M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $29.61M 10-Q · filed 2022-05-04 | $56.26M derived: sum of 2 quarters · filed 2023-03-01 | $80.60M derived: sum of 3 quarters · filed 2023-03-01 | $103.23M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $26.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $50.99M derived: sum of 2 quarters · filed 2023-03-01 | $73.63M derived: sum of 3 quarters · filed 2023-03-01 | $98.88M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $24.34M 10-Q · filed 2021-11-04 | $46.97M derived: sum of 2 quarters · filed 2021-11-04 | $72.22M 10-Q · filed 2021-11-04 | $97.48M derived: sum of 4 quarters · filed 2022-03-07 | ||
| 2020-06-30 | $22.64M 10-Q · filed 2021-08-09 | $47.89M 10-Q · filed 2021-08-09 | $73.15M derived: sum of 3 quarters · filed 2022-03-07 | $106.89M derived: sum of 4 quarters · filed 2022-03-07 | ||
| 2020-03-31 | $25.25M 10-Q · filed 2021-05-04 | $50.51M derived: sum of 2 quarters · filed 2022-03-07 | $84.26M derived: sum of 3 quarters · filed 2022-03-07 | $115.91M derived: sum of 4 quarters · filed 2022-03-07 | ||
| 2019-12-31 | $25.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $59.00M derived: sum of 2 quarters · filed 2022-03-07 | $90.66M derived: sum of 3 quarters · filed 2022-03-07 | $115.43M 10-K · filed 2022-03-07 | ||
| 2019-09-30 | $33.74M 10-Q · filed 2020-11-04 | $65.40M derived: sum of 2 quarters · filed 2020-11-04 | $90.17M 10-Q · filed 2020-11-04 | $109.84M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-06-30 | $31.66M 10-Q · filed 2020-08-10 | $56.43M 10-Q · filed 2020-08-10 | $76.09M derived: sum of 3 quarters · filed 2021-02-25 | $97.98M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2019-03-31 | $24.77M 10-Q · filed 2020-05-06 | $44.44M derived: sum of 2 quarters · filed 2021-02-25 | $66.32M derived: sum of 3 quarters · filed 2021-02-25 | $80.74M derived: sum of 4 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $19.66M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $41.55M derived: sum of 2 quarters · filed 2021-02-25 | $55.97M derived: sum of 3 quarters · filed 2021-02-25 | $71.72M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $21.89M 10-Q · filed 2019-11-08 | $36.30M derived: sum of 2 quarters · filed 2019-11-08 | $52.06M 10-Q · filed 2019-11-08 | $62.21M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-06-30 | $14.41M 10-Q · filed 2019-08-08 | $30.17M 10-Q · filed 2019-08-08 | $40.32M derived: sum of 3 quarters · filed 2020-03-02 | $49.41M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2018-03-31 | $15.76M 10-Q · filed 2019-05-07 | $25.91M derived: sum of 2 quarters · filed 2020-03-02 | $34.99M derived: sum of 3 quarters · filed 2020-03-02 | $44.55M derived: sum of 4 quarters · filed 2020-03-02 | ||
| 2017-12-31 | $10.15M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $19.24M derived: sum of 2 quarters · filed 2020-03-02 | $28.79M derived: sum of 3 quarters · filed 2020-03-02 | $38.78M 10-K · filed 2020-03-02 | ||
| 2017-09-30 | $9.09M 10-Q · filed 2018-11-08 | $18.64M derived: sum of 2 quarters · filed 2018-11-08 | $28.63M 10-Q · filed 2018-11-08 | $34.56M derived: sum of 4 quarters · filed 2019-02-28 | ||
| 2017-06-30 | $9.55M 10-Q · filed 2018-08-07 | $19.54M 10-Q · filed 2018-08-07 | $25.47M derived: sum of 3 quarters · filed 2019-02-28 | $29.76M derived: sum of 4 quarters · filed 2019-02-28 | ||
| 2017-03-31 | $9.99M 10-Q · filed 2018-05-08 | $15.92M derived: sum of 2 quarters · filed 2019-02-28 | $20.20M derived: sum of 3 quarters · filed 2019-02-28 | $23.69M derived: sum of 4 quarters · filed 2019-02-28 | ||
| 2016-12-31 | $5.93M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $10.22M derived: sum of 2 quarters · filed 2019-02-28 | $13.70M derived: sum of 3 quarters · filed 2019-02-28 | $19.71M 10-K · filed 2019-02-28 | ||
| 2016-09-30 | $4.29M 10-Q · filed 2017-11-07 | $7.78M derived: sum of 2 quarters · filed 2017-11-07 | $13.78M 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $3.49M 10-Q · filed 2017-08-10 | $9.49M 10-Q · filed 2017-08-10 | ||||
| 2016-03-31 | $6.00M 10-Q · filed 2017-05-12 | |||||
| 2015-12-31 | $20.89M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |